

Patient ID SA00095501	Patient Name TESTING, SHARI	Birth Date 1999-01-01	Gender F	Age 18
Order Number SA00095501	Client Order Number SA00095501	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 11 Aug 2017 00:00		

Ki67 Breast IHC Automated

Case Number CR-17-7844

Interpretation

MCR

Left breast, original accession: S17-123, block: S17-123-A1

SPECIAL PROCEDURE REPORT

Breast Biomarker(s) for:

Invasive or metastatic breast carcinoma

Result(s):

Ki-67 by Immunohistochemistry (IHC) Percentage of Positive Nuclei 1.2%

METHOD AND SCORING

Ki-67 (MIB-1) Breast Cancer Automated Scoring Method: Ki-67 (MIB-1) proliferation data must be interpreted within the clinical context for which the test was ordered. Recent studies have suggested that Ki-67 (MIB-1) analysis of paraffin-embedded breast cancer tissue specimens may provide useful prognostic information.

1. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 2005 Oct 1;23(28):7212-7220
2. de Azambuja E, Cardoso F, de Castro G Jr, et al. Ki-67 as prognostic marker in early breast cancer; a meta-analysis of published studies involving 12, 155 patients. Br J Cancer 2007 May 21; 96(10):1504-1513 Epub 2007 Apr 24 Immunohistochemical staining of the Ki-67 antigen in formalin-fixed paraffin-embedded tissue sections has been validated by our laboratory, using the MIB-1 clone and a proprietary detection system. All controls show appropriate reactivity. Ki-67(MIB-1)-stained slides are scanned using the Aperio ScanScope instrument, which captures digital images of the patient slide. A technologist views the digitized image on a computer monitor and using a tracing tool available in ImageScope (Aperio Technologies INC), traces around areas of invasive or metastatic cancer capturing no less than 75% of the total cancer within the image. The traced areas are then analyzed using an image analysis algorithm that renders the percentage of positive-staining tumor nuclei. The slides and test results are then reviewed by a pathologist who provides a final interpretation. This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Material Received

MCR

A. S17-123: Left breast
1 block

Report electronically signed by

MCR

Taofic Mounajjed, M.D. 3-5281

Tumor type

MCR

Primary invasive breast carcinoma

Tumor classification

MCR

Invasive breast carcinoma

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292



Patient ID SA00095501	Patient Name TESTING, SHARI	Birth Date 1999-01-01	Gender F	Age 18
Order Number SA00095501	Client Order Number SA00095501	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7028846 DLMP Rochester		Collected 11 Aug 2017 00:00		

Received: 14 Aug 2017 12:19

Reported: 14 Aug 2017 14:28

Test
Environment
PATHDX Template

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292